Skip to main content

Advertisement

Table 1 Weight, water intake and urine albumin data in lean controls and leptin-deficient (ob/ob−/−) mice

From: SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice

  Weight Water intake (ml/mouse/day) Urine albumin (µg/ml)
Body (g) Heart (g) Kidney (g)
Lean (n = 12)
 BL 28 ± 1 n.d n.d 6.7 ± 0.6 9.5 ± 3.0 (n = 2)
 5 weeks 30 ± 1 n.d n.d 5.0 ± 1.2 7.1 ± 2.0 (n = 3)
 10 weeks 33 ± 2 0.18 ± 0.04 0.21 ± 0.01 5.4 ± 0.7 7.6 ± 1.4 (n = 6)
ob/ob−/− untreated (n = 21)
 BL 47 ± 4** n.d n.d 8.2 ± 2.2* 22.7 ± 5.1 (n = 16)
 5 weeks 53 ± 6** n.d n.d 9.0 ± 4.0* 15.1 ± 3.1 (n = 19)
 10 weeks 60 ± 6** 0.18 ± 0.02 0.22 ± 0.03 8.9 ± 3.8** 10.95 ± 1.8 (n = 12)
ob/ob−/− treated (n = 22)
 BL 48 ± 3** n.d n.d 8.1 ± 1.0* 33.0 ± 4.1 (n = 16)
 5 weeks 54 ± 3** n.d n.d 13.5 ± 1.5* 7.2 ± 1.1 (n = 9)
 10 weeks 58 ± 3** 0.20 ± 0.03 0.24 ± 0.04* 14.4 ± 2.8** 5.2 ± 0.3 (n = 5)
  1. To monitor the progression of obesity, body weight was studied over time, and as a measure of animal health, water intake was recorded. Wet heart and kidney weight were also recorded at the end of the treatment period. Statistical significance within each time point by one-way ANOVA and Tukey’s post hoc. Values are presented as mean ± SD for parametric data and mean ± SEM for non-parametric data, where *p < 0.05 and **p < 0.01 and p ≤ 0.05 for ob/ob−/− treated and untreated group